Engelhorn returns to the helm at Corange
This article was originally published in Clinica
The Engelhorn saga continues. Despite being forcibly removed from the board of directors in 1994 and agreeing in the ensuing boardroom battle not to stand for re-election, Curt Engelhorn was on May 29th re-appointed as chairman of Corange, the Bermuda-registered parent of Boehringer Mannheim (Germany) and DePuy (US).
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.